Archive | July, 2016

Biotech Stocks Strike a Bullish Tone: BLUE, IBB, REGN, SGEN…Update-2

Bullish Tone-Large Cap Biopharmaceutical Earnings Updates 8/5 Regeneron (REGN) shares fell another 2.4% to $423 despite a jump of 23% on Eylea sales to $832M compared to $655 M in the prior-year quarter. Higher expenses cut profitability as GAAP income was up only 1%.Financial results were reported at the close on Wednesday. Full year growth […]

Continue Reading 0

Biotechs Get a Turbo Boost from Biogen(BIIB)…Update-1 GILD

Update-1… Gilead Sciences (GILD) Sells Off on earnings Gilead Sciences (GILD) sold off over 4% after hours after releasing second quarter sales of $7.7B and earnings of $3.08/sh. Q2 profit forecast beat. The full year revenue forecast was also cut slightly by $1B to the $29,5B-$31.5B range. Pricing pressures continued on Hep-C drugs and new […]

Continue Reading 0

Biotech Bear Market Rally: Can Active Funds Beat the ETFs?

Biotech Bear Market Rally Headed Toward Triple Top The biotech rally has wobbly legs moving briskly from the Brexit lows but with choppy action recently.This would be the third time biotech stocks will try to gain momentum toward higher highs although lows are holding. While technicals will give you the navigation for weighting  in the sector […]

Continue Reading 0

Biotech Rally Up 8% from Brexit Bottom: Rayno Biopharmaceutical Portfolio Update: July 11, 2016…Update-1

Update-1… 7/12/16 Dow and S&P Hit Record Highs, Awaiting Q2 Earnings-Risk Still On-Biotech Stocks Lag The market continued its post-BREXIT rally helped by low interest rates and WTI crude up 4.56% to $46.80. Gold eased off and the dollar was up. We are still rallying off last Friday’s job report and Alcoa (AA) earnings yesterday. […]

Continue Reading 0

Foundation Medicine (FMI): New Pick Added To Raygent Core Portfolio

Foundation Medicine (FMI) New Pick at $20.40 We have added Foundation Medicine (FMI) to our core portfolio because of their leadership position in pharmacogenomics and molecular medicine for cancer care. The Foundation One genomic profile helps physicians make treatment decisions for patients with cancer by identifying the molecular growth drivers of their cancers and helping oncologists […]

Continue Reading 0

Large Cap Biopharmaceuticals-Valuation Models 2016

Biopharmaceutical Valuations Look Attractive Sector Poised for Rebound by Year End This is a continuing review of large cap biopharmaceutical valuation metrics to determine which companies can deliver growth from their broad pipelines. The biotech sector has underperformed the market because of the severe correction in August/September of 2015 followed by another downdraft in January […]

Continue Reading 0